Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the ...
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Black Diamond Therapeutics (BDTX – Research ...